June 28, 2021
4 min watch
Save
VIDEO: Data support ‘favorable benefit/risk profile’ in management of DME with Iluvien
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective from the virtual ARVO meeting, Michael Singer, MD, discusses increase in IOP viewed as a “24-month snapshot” in the completer data of the PALADIN study.
The PALADIN study is an ongoing 3-year prospective phase 4 study looking at use of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) in patients with diabetic macular edema.
Published by:
Sources/Disclosures
Collapse
Source:
Singer M. Time to IOP > 25 mm Hg IOP in the PALADIN 24-month completer data. Presented at: Association for Research in Vision and Ophthalmology annual meeting; May 1-7, 2021 (virtual meeting).
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.